Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $105.00 Price Target at Cantor Fitzgerald

Key Points

• Ultragenyx Pharmaceutical's price target has been reduced from $112.00 to $105.00 by Cantor Fitzgerald, yet the firm maintains an "overweight" rating on the stock, suggesting a potential upside of 292.01% from the current price.
• Wells Fargo has also downgraded its target for the stock significantly to $65.00, while other firms such as Guggenheim and HC Wainwright have positive ratings with targets ranging from $64.00 to $80.00.
• During recent trading, Ultragenyx shares fell by $2.14 to reach $26.79, marking a significant decrease compared to its 52-week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Free Report) had its price objective lowered by Cantor Fitzgerald from $112.00 to $105.00 in a research note released on Wednesday morning,Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company's stock. Cantor Fitzgerald also issued estimates for Ultragenyx Pharmaceutical's FY2025 earnings at ($5.19) EPS and FY2026 earnings at ($3.21) EPS.

Other analysts also recently issued research reports about the stock. Wedbush dropped their target price on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a report on Monday, July 14th. Morgan Stanley dropped their price objective on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a research note on Monday, July 14th. HC Wainwright raised Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 target price on the stock in a research note on Monday, July 28th. William Blair began coverage on Ultragenyx Pharmaceutical in a research report on Wednesday, May 28th. They issued an "outperform" rating and a $65.00 target price for the company. Finally, Wells Fargo & Company cut their price target on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating on the stock in a research note on Thursday, July 10th. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, Ultragenyx Pharmaceutical presently has a consensus rating of "Moderate Buy" and an average price target of $82.17.

Ultragenyx Pharmaceutical Trading Down 1.2%

Ultragenyx Pharmaceutical stock traded down $0.34 during mid-day trading on Wednesday, hitting $27.50. The company's stock had a trading volume of 224,158 shares, compared to its average volume of 1,283,931. The stock's fifty day moving average is $33.45 and its two-hundred day moving average is $36.87. The firm has a market capitalization of $2.60 billion, a PE ratio of -4.98 and a beta of 0.25. Ultragenyx Pharmaceutical has a 1 year low of $25.81 and a 1 year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.27) by $0.10. The firm had revenue of $166.50 million during the quarter, compared to the consensus estimate of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 214.21% and a negative net margin of 87.34%. The company's quarterly revenue was up 13.2% on a year-over-year basis. During the same period last year, the company earned ($1.52) EPS. On average, equities analysts expect that Ultragenyx Pharmaceutical will post -5.18 EPS for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the business's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $37.39, for a total transaction of $89,922.95. Following the completion of the sale, the director owned 15,344 shares in the company, valued at $573,712.16. The trade was a 13.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 5.50% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Parallel Advisors LLC lifted its position in Ultragenyx Pharmaceutical by 1,061.9% in the second quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 669 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Ultragenyx Pharmaceutical by 76.2% in the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 323 shares during the period. Aster Capital Management DIFC Ltd purchased a new position in Ultragenyx Pharmaceutical during the 4th quarter worth approximately $35,000. ANTIPODES PARTNERS Ltd acquired a new position in Ultragenyx Pharmaceutical during the first quarter worth approximately $57,000. Finally, Headlands Technologies LLC purchased a new stake in Ultragenyx Pharmaceutical in the first quarter valued at approximately $59,000. Institutional investors and hedge funds own 97.67% of the company's stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.